Myriad Genetics (MYGN) and PATHOMIQ have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQs AI technology platform for prostate cancer, in the United States. Adding PATHOMIQ_PRAD to Myriads Oncology Solutions allows Myriad to provide urologist and radiation oncologists with molecular and AI-powered testing solutions to inform decisions both before treatment at the time of biopsy for active surveillance and following surgery or radiation treatment.
Myriad plans to commercially launch its first AI-driven prostate cancer clinical test later in the current year.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.